PriceTargets.com logo

Oncolytics Biotech - ONCY Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 308.16%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$0.98 As of 11/15/2024 01:00 AM ET
▼ -0.03 (-2.97%)

This chart shows the closing price for ONCY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Oncolytics Biotech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ONCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ONCY

Analyst Price Target is $4.00
▲ +308.16% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Oncolytics Biotech in the last 3 months. The average price target is $4.00, with a high forecast of $5.00 and a low forecast of $3.00. The average price target represents a 308.16% upside from the last price of $0.98.

This chart shows the closing price for ONCY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Oncolytics Biotech. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/25/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/23/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/19/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/14/2024Raymond JamesUpgradeModerate Buy
11/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
11/13/2024Leede FinancialDowngradeStrong-Buy ➝ Moderate Buy
9/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
8/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
4/4/2024Raymond JamesInitiated CoverageOutperform$3.00
2/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
1/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
1/4/2024HC WainwrightReiterated RatingBuy ➝ Buy$5.00
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $5.00
8/16/2023HC WainwrightReiterated RatingBuy ➝ Buy$15.00
3/14/2023HC WainwrightReiterated RatingBuy
3/6/2023Canaccord Genuity GroupLower TargetBuy$6.00 ➝ $5.00
3/6/2023Cantor FitzgeraldReiterated RatingOverweight
10/6/2022Maxim GroupInitiated CoverageBuy$3.00
3/7/2022HC WainwrightReiterated RatingBuy
3/4/2022Leede Jones GabReiterated RatingSpeculative Buy
1/27/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$7.00 ➝ $6.00
8/16/2021HC WainwrightReiterated RatingBuy$15.00
2/24/2021Leede Jones GabReiterated RatingSpeculative Buy
2/17/2021HC WainwrightInitiated CoverageBuy$15.00
6/16/2020Echelon Wealth PartnersReiterated RatingSpeculative Buy
5/11/2020Roth CapitalReiterated RatingBuy$9.00
5/11/2020Royal Bank of CanadaLower TargetOutperform$9.00 ➝ $6.00
1/2/2020Roth CapitalBoost TargetBuy$6.80 ➝ $9.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
4/21/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
5/21/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
6/20/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 1 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/19/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
10/18/2024
  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 3 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Oncolytics Biotech logo
Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Read More

Today's Range

Now: $0.98
Low: $0.97
High: $1.03

50 Day Range

MA: $1.09
Low: $0.85
High: $1.40

52 Week Range

Now: $0.98
Low: $0.84
High: $1.75

Volume

245,358 shs

Average Volume

407,103 shs

Market Capitalization

$75.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Oncolytics Biotech?

The following Wall Street sell-side analysts have issued stock ratings on Oncolytics Biotech in the last twelve months: Cantor Fitzgerald, HC Wainwright, Leede Financial, and Raymond James.
View the latest analyst ratings for ONCY.

What is the current price target for Oncolytics Biotech?

0 Wall Street analysts have set twelve-month price targets for Oncolytics Biotech in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 308.2%. HC Wainwright has the highest price target set, predicting ONCY will reach $5.00 in the next twelve months. Raymond James has the lowest price target set, forecasting a price of $3.00 for Oncolytics Biotech in the next year.
View the latest price targets for ONCY.

What is the current consensus analyst rating for Oncolytics Biotech?

Oncolytics Biotech currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ONCY will outperform the market and that investors should add to their positions of Oncolytics Biotech.
View the latest ratings for ONCY.

What other companies compete with Oncolytics Biotech?

Other companies that are similar to Oncolytics Biotech include Enlivex Therapeutics, Chembio Diagnostics, YS Biopharma, Alpha Teknova and iTeos Therapeutics. Learn More about companies similar to Oncolytics Biotech.

How do I contact Oncolytics Biotech's investor relations team?

Oncolytics Biotech's physical mailing address is 1167 Kensington Crescent Suite 210, Calgary A0, T2N 1X7. The company's listed phone number is (403) 670-7377 and its investor relations email address is [email protected]. The official website for Oncolytics Biotech is www.oncolyticsbiotech.com. Learn More about contacing Oncolytics Biotech investor relations.